Pfizer has won FDA approval for its PARP inhibitor Talzenna in castration-resistant prostate cancer (CRPC) in a combination that it hopes will help it challenge AstraZenec
Johnson & Johnson has picked up its first regulatory approval worldwide for Akeega, a fixed-dose combination of a PARP inhibitor and anti-androgen therapy, as a treatm
Clovis Oncology has said it may not have enough cash to fund continuing operations beyond January next year, as it struggles to reverse a decline in sales of PARP inhibitor Rubraca.
AstraZeneca and Merck's PARP inhibitor Lynparza has carved out blockbuster revenues across uses in breast, ovarian, prostate and pancreatic cancer, but colorectal cancer won’t be added to t
The FDA has cleared AstraZeneca and Merck & Co's Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending its lead over pretenders to its PARP inhibitor crown.
AstraZeneca's PARP inhibitor Lynparza should not be made available routinely on the NHS n England and Wales as a treatment for prostate cancer, according to cost effectiveness agency NICE.<